Awaiting development: Guidance and quality standards
Showing 281 to 286 of 286
| Title | Type |
|---|---|
| Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477] | Technology appraisal guidance |
| Zavegepant for treating acute migraine [TSID11998] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |